Quick Answer
Flavanol Cognitive Performance Randomized Trial has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: 6 2,7–9 10 11 12 13 Although amyloid-beta and tau hypotheses have been the primary hypotheses in the underlying pathogenesis of AD, emerging evidence suggests that amyloidegenesis can be exacerbated by oxidative stress, leading to AD development and progression [].
Key Takeaways
- 016 2,7–9 10 11 12 13 Although amyloid-beta and tau hypotheses have been the primary hypotheses in the underlying pathogenesis of AD, emerging evidence suggests that amyloidegenesis can be exacerbated by oxidative stress, leading to AD development and progression []. [Zainuddin Muhammad-Safuan (2026)]
- 02Growing evidence suggests that oxidative stress and impairment of innate antioxidative defence may precede the pathological features of AD and clinical manifestations [,]. [Zainuddin Muhammad-Safuan (2026)]
- 03Therefore, this review aims to highlight evidence of oxidative biomarkers across different specimens, including post-mortem brain and biofluids in AD patients compared to the healthy population. [Zainuddin Muhammad-Safuan (2026)]
- 041 1 2 1 3 4 5 Alzheimer's disease (AD) is the most prominent age-related neurodegenerative disease in the world []. [Zainuddin Muhammad-Safuan (2026)]
The current Migaku evidence database contains 2 reusable source documents for Flavanol Cognitive Performance Randomized Trial. This answer focuses on strength of evidence and what the studies can or cannot prove.
- 6 2,7–9 10 11 12 13 Although amyloid-beta and tau hypotheses have been the primary hypotheses in the underlying pathogenesis of AD, emerging evidence suggests that amyloidegenesis can be exacerbated by oxidative stress, leading to AD development and progression []. [Zainuddin Muhammad-Safuan (2026); evidence level 3]
- Growing evidence suggests that oxidative stress and impairment of innate antioxidative defence may precede the pathological features of AD and clinical manifestations [,]. [Zainuddin Muhammad-Safuan (2026); evidence level 3]
- Therefore, this review aims to highlight evidence of oxidative biomarkers across different specimens, including post-mortem brain and biofluids in AD patients compared to the healthy population. [Zainuddin Muhammad-Safuan (2026); evidence level 3]
- 1 1 2 1 3 4 5 Alzheimer's disease (AD) is the most prominent age-related neurodegenerative disease in the world []. [Zainuddin Muhammad-Safuan (2026); evidence level 3]
- The number of individuals affected by dementia and cognitive decline is progressively increasing, becoming a serious global health challenge. [Sbai O (2026); evidence level 4]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources